Comparison
Klaim vs. Thrivory.
Claim funding is one financial action. Klaim is the CFO control system for forecasting, financing, and recovering the entire healthcare AR portfolio, including the receivables that should never be funded at all.
At a glance
Prediction-to-funding vs. portfolio-wide control.
| Klaim | Thrivory | |
|---|---|---|
| Core job | A CFO control system covering the full financial disposition of every receivable | A financial transaction layer behind claims, predicting reimbursement and funding it same-day |
| Primary user | CFOs and treasury teams managing a whole AR portfolio | Platforms and providers needing embedded claim-funding infrastructure |
| Output | A forecast, accelerate, or recover decision for every receivable, plus enterprise cash forecasting | An expected reimbursement, denial-risk score, and a same-day funding offer |
| Recovery | Manages distressed and at-risk receivables through a dedicated recovery workflow | Not a central part of public positioning |
| Capital sourcing | Designed to route eligible receivables across multiple capital sources under CFO policy | Not clearly central to public positioning |
Capability matrix
Where the overlap ends.
Klaim and Thrivory overlap on claim-level prediction and funding. The difference is what happens before and after that moment: portfolio forecasting, neutral decisioning, capital routing, and recovery.
| Capability | Klaim | Thrivory |
|---|---|---|
| Expected reimbursement | ||
| Expected payment date | ||
| Denial-risk prediction | ||
| Same-day claim funding | ||
| CFO enterprise cash forecast | ||
| Neutral wait-vs-fund recommendation | ||
| Multi-funder capital marketplace | ||
| Managed AR recovery | ||
| Healthcare treasury policies | ||
| Portfolio liquidity scenarios |
The detail
Why the comparison comes up.
What each one decides
Klaim decides what should happen to a receivable: stay in the normal cycle, get accelerated into cash now, or get flagged for recovery. The decision is neutral. It is not biased toward funding every claim.
Thrivory predicts what a claim is worth and offers to fund it same-day. The core product motion is prediction into funding, not a neutral hold/accelerate/recover decision across the whole book.
Scope of the portfolio
Built around the full receivable book (performing AR, accelerated AR, and at-risk AR), with a consolidated CFO view across all three.
Built around individual claims moving through a funding pipeline, embedded behind a platform or provider's existing claim flow.
What happens when a claim goes bad
Recovery is a first-class workflow: Klaim detects deterioration, estimates expected net recovery, and routes the claim to an internal team, AI agent, or recovery partner.
Recovery is not central to Thrivory's public proposition. Its strength is upstream, at prediction and funding.
Where the capital comes from
Designed to route eligible receivables to the best available capital source under CFO-defined policy, whether Klaim capital, bank capital, or other approved liquidity sources.
Funds claims same-day, but a multi-funder marketplace with CFO policy controls is not clearly central to its current positioning.
Who each is for
Be honest about the fit.
If you need embedded claim funding, fast.
- You need embedded, API-first claim funding inside an existing platform or workflow.
- Your priority is same-day funding speed on individual claims, not portfolio-wide treasury control.
- You do not currently need a recovery workflow for denied, underpaid, or aging claims.
If you need a CFO control system for the whole book.
- You are a CFO who needs one system that forecasts cash, decides what to accelerate, and recovers what's at risk across the whole AR book.
- You want a neutral recommendation, including the times the right answer is to wait, not fund.
- You need recovery execution for claims that have already gone off track, not just funding for healthy ones.
Common questions.
Is Klaim just a Thrivory competitor for claim funding?
Same-day funding is one of several actions Klaim can take. Thrivory's core motion is prediction into funding. Klaim's core motion is a neutral decision (forecast, accelerate, or recover) applied to every receivable in the portfolio, including the ones that should not be funded at all.
Does Klaim do denial-risk prediction like Thrivory?
Yes. Expected reimbursement, expected payment date, and denial-risk prediction are core to both. The difference shows up after the prediction: Klaim adds enterprise cash forecasting, multi-funder routing, and managed recovery on top of it.
Can a CFO use both?
Thrivory's claim-level funding rail could function as one capital source inside Klaim's broader decisioning layer. Klaim does not require you to abandon existing funding relationships. It decides when funding is the right action and which source to route to.
See the full financial action, not only the funding offer.
Forecast what is coming, accelerate what you need, and recover what is at risk, in one CFO-controlled system.